Evidence map›Paper›PMID 39431293›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Parkinson Disease -Targeted Nanocapsules for Synergistic Treatment: Combining Dopamine Replacement and Neuroinflammation Mitigation.

Ziyao Liu, Shijun Xiang, Bei Chen, Jian Li, Dingcheng Zhu, Hongjuan Xu, Shuo Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ziyao LiuDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
Shijun XiangDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
Bei ChenDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
Jian LiDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
Dingcheng ZhuCollege of Material, Chemistry and Chemical Engineering, Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Hangzhou Normal University, Hangzhou, 311121, China.
Hongjuan XuDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
Shuo HuDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.ORCID 0000-0003-0998-8943

Funding

Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases 2020LNJJ01National Natural Science Foundation of China 82272045National Natural Science Foundation of China 82303533National Natural Science Foundation of China 91859207Science and Technology Innovation Program of Hunan Province 2021RC2015Science and Technology Innovation Program of Hunan Province 2021RC4056Youth foundation of Hunan Province 2022JJ40764Youth foundation of Hunan Province 2023JJ41007
6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by dopamine (DA) neuron loss and neuroinflammation. This study develops carrier-free nanocapsules (NCs) for targeted delivery of DA and catalase (CAT) to the PD brain, addressing both DA depletion and neuroinflammation simultaneously. The NCs are engineered by DA and 4-formylphenylboronic acid co-loading with cRGD-modified CAT (CAT-cRGD) and surface-modifying with Angiopep-2 (Ang). Ang targets the blood-brain barrier (BBB), enhancing brain delivery, while cRGD targets upregulated integrin receptors in the PD-affected BBB. The NCs showed a 1.4-fold increase in parkinsonian brain targeting efficiency compared to normal mice. In PD mice models, NCs demonstrated a stable increase in learning and memory, enhanced locomotor activity, and improved motor coordination. DA supplementation significantly enhanced dopaminergic signaling, increasing DA levels 1.8- and 3.5-fold in the striatum and substantia nigra, respectively. Additionally, delivered CAT effectively reduced neuroinflammation by mitigating endoplasmic reticulum stress, slowing disease progression, and protecting DA from oxidation. This innovative approach using PD-targeted NCs represents a synergistic strategy for PD treatment, combining symptomatic relief with disease progression intervention.

Indexed as

Disease Models, AnimalDopamineNanocapsulesNeuroinflammatory DiseasesParkinson DiseaseAnimalsBlood-Brain BarrierCatalaseMaleMiceMice, Inbred C57BLCatalaseDopamineNanocapsulescarrier‐free delivery systemmacromolecule deliveryneurotransmitter deliveryParkinson diseasesynergistic therapy

Identifiers

PMID39431293
PMCPMC11633476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.